Senior Research Scientist University of Mississippi University, Mississippi
In the evolving landscape of pharmaceutical biotechnology, genetically engineered microbes are being reimagined as delivery vehicles for recombinant protein vaccines, particularly in the fight against cancer. Bacterial species such as Escherichia coli, Salmonella, and Listeria can be modified to express therapeutic proteins, cytokines, or enzymes that activate anticancer prodrugs directly within tumor microenvironments. These microbial systems offer the significant benefit of localized immune stimulation while minimizing systemic side effects.
Emerging strategies, such as microencapsulation, 3D bioprinting, and nanoparticle-assisted delivery, are further enhancing the precision and efficacy of microbial therapeutics. This presentation explores recent advances in microbial vaccine engineering and delivery, illustrating how engineered bacteria are advancing cancer immunotherapy and shaping the next generation of recombinant vaccines.
Learning Objectives:
Upon completion, participants will be able to describe microbial vaccine development, explain bacterial targeting mechanisms in cancer therapy, and evaluate delivery platforms enhancing stability and efficacy of recombinant protein-based treatments.
